Deepak Tiwari
Profile
Deepak Tiwari is a professional with former positions at Cornerstone Pharmaceuticals, Inc. as Vice President & Head-CMC Operations and at GlycoMimetics, Inc. as Vice President-Technical Operations.
He holds a graduate and doctorate degree from St. John's University and an undergraduate degree from the University of Delhi.
Former positions of Deepak Tiwari
Companies | Position | End |
---|---|---|
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Corporate Officer/Principal | - |
GLYCOMIMETICS, INC. | Chief Tech/Sci/R&D Officer | - |
Training of Deepak Tiwari
St. John's University | Doctorate Degree |
University of Delhi | Undergraduate Degree |
Experiences
Positions held
Linked companies
Listed companies | 1 |
---|---|
GLYCOMIMETICS, INC. | Health Technology |
Private companies | 1 |
---|---|
Cornerstone Pharmaceuticals, Inc.
Cornerstone Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Rafael Pharmaceuticals, Inc. develops anti-cancer drug delivery technology. It produces highly selective and effective anti-cancer agents with minimal toxic effects on normal cells and tissues by attacking regulatory processes that are unique to cancer and not found in healthy cells. The firm would ensure a significant improvement in the safety profile of cancer treatment. The firm provides CPI-613, Altered Energy Metabolism Directed (AEMD) platform, targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. The company was founded by Robert G. L. Shorr and is headquartered in Cranbury, NJ. | Commercial Services |
- Stock Market
- Insiders
- Deepak Tiwari